|
1
|
Rice TW, Rusch VW, Apperson-Hansen C, et
al: Worldwide esophageal cancer collaboration. Dis Esophagus.
22:1–8. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Allum WH, Stenning SP, Bancewicz J, Clark
PI and Langley RE: Long-term results of a randomized trial of
surgery with or without preoperative chemotherapy in esophageal
cancer. J Clin Oncol. 27:5062–5067. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Edge S, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th. Springer;
Chicago: pp. 67–72. 2010
|
|
4
|
Carlsson P and Mahlapuu M: Forkhead
transcription factors: Key players in development and metabolism.
Dev Biol. 250:1–23. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Katoh M and Katoh M: Human FOX gene family
(Review). Int J Oncol. 25:1495–1500. 2004.PubMed/NCBI
|
|
6
|
Wang T, Tamakoshi T, Uezato T, Shu F,
Kanzaki-Kato N, Fu Y, Koseki H, Yoshida N, Sugiyama T and Miura N:
Forkhead transcription factor FoxF2 (LUN)-deficient mice exhibit
abnormal development of secondary palate. Dev Biol. 259:83–94.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ormestad M, Astorga J, Landgren H, Wang T,
Johansson BR, Miura N and Carlsson P: Foxf1 and Foxf2 control
murine gut development by limiting mesenchymal Wnt signaling and
promoting extracellular matrix production. Development.
133:833–843. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jochumsen U, Werner R, Miura N,
Richter-Unruh A, Hiort O and Holterhus PM: Mutation analysis of
FOXF2 in patients with disorders of sex development (DSD) in
combination with cleft palate. Sex Dev. 2:302–308. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu L, Wynn J, Ma L, et al: De novo copy
number variants are associated with congenital diaphragmatic
hernia. J Med Genet. 49:650–659. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Westergren R, Nilsson D, Heglind M, Arani
Z, Grände M, Cederberg A, Ahrén B and Enerbäck S: Overexpression of
Foxf2 in adipose tissue is associated with lower levels of IRS1 and
decreased glucose uptake in vivo. Am J Physiol Endocrinol Metab.
298:E548–E554. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aitola M, Carlsson P, Mahlapuu M, Enerbäck
S and Pelto-Huikko M: Forkhead transcription factor FoxF2 is
expressed in mesodermal tissues involved in epithelio-mesenchymal
interactions. Dev Dyn. 218:136–149. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nik AM, Reyahi A, Pontén F and Carlsson P:
Foxf2 in intestinal fibroblasts reduces numbers of Lgr5+
stem cells and adenoma formation by inhibiting Wnt signaling.
Gastroenterology. 144:1001–1011. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
van den Brink GR and Rubin DC: Foxf2: A
mesenchymal regulator of intestinal adenoma development.
Gastroenterology. 144:873–876. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kong PZ, Yang F, Li L, Li XQ and Feng YM:
Decreased FOXF2 mRNA expression indicates early-onset metastasis
and poor prognosis for breast cancer patients with histological
grade II tumor. PLoS ONE. 8:e615912013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hirata H, Ueno K, Shahryari V, Deng G,
Tanaka Y, Tabatabai ZL, Hinoda Y and Dahiya R: MicroRNA-182-5p
promotes cell invasion and proliferation by down regulating FOXF2,
RECK and MTSS1 genes in human prostate cancer. PLoS ONE.
8:e555022013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sachdeva M, Mito JK, Lee CL, et al:
MicroRNA-182 drives metastasis of primary sarcomas by targeting
multiple genes. J Clin Invest. 124:4305–4319. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lei R, Tang J, Zhuang X, et al:
Suppression of MIM by microRNA-182 activates RhoA and promotes
breast cancer metastasis. Oncogene. 33:1287–1296. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
van der Heul-Nieuwenhuijsen L, Dits NF and
Jenster G: Gene expression of forkhead transcription factors in the
normal and diseased human prostate. BJU Int. 103:1574–1580. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
van der Heul-Nieuwenhuijsen L, Dits N, Van
Ijcken W, de Lange D and Jenster G: The FOXF2 pathway in the human
prostate stroma. Prostate. 69:1538–1547. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang MH, Yu J, Jiang DM, Li WL, Wang S and
Ding YQ: microRNA-182 targets special AT-rich sequence-binding
protein 2 to promote colorectal cancer proliferation and
metastasis. J Transl Med. 12:1092014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang T, Wong HK, Gu W, Yu MY, To KF, Wang
CC, Wong YF, Cheung TH, Chung TK and Choy KW: MicroRNA-182 plays an
onco-miRNA role in cervical cancer. Gynecol Oncol. 129:199–208.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ning FL, Wang F, Li ML, Yu ZS, Hao YZ and
Chen SS: MicroRNA-182 modulates chemosensitivity of human non-small
cell lung cancer to cisplatin by targeting PDCD4. Diagn Pathol.
9:1432014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gu ZD, Li JY, Li M, Gu J, Shi XT, Ke Y and
Chen KN: Matrix metalloproteinases expression correlates with
survival in patients with esophageal squamous cell carcinoma. Am J
Gastroenterol. 100:1835–1843. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Murray GI, Duncan ME, O'Neil P, Melvin WT
and Fothergill JE: Matrix metalloproteinase-1 is associated with
poor prognosis in colorectal cancer. Nat Med. 2:461–462. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pellikainen JM, Ropponen KM, Kataja VV,
Kellokoski JK, Eskelinen MJ and Kosma VM: Expression of matrix
metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special
reference to activator protein-2, HER2 and prognosis. Clin Cancer
Res. 10:7621–7628. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Koskensalo S, Mrena J, Wiksten JP,
Nordling S, Kokkola A, Hagström J and Haglund C: MMP-7
overexpression is an independent prognostic marker in gastric
cancer. Tumour Biol. 31:149–155. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiang H, Li Q, He C, et al: Activation of
the Wnt pathway through Wnt2 promotes metastasis in pancreatic
cancer. Am J Cancer Res. 4:537–544. 2014.PubMed/NCBI
|
|
28
|
Dey N, Barwick BG, Moreno CS, et al: Wnt
signaling in triple negative breast cancer is associated with
metastasis. BMC Cancer. 13:5372013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yamamoto H, Oue N, Sato A, Hasegawa Y,
Yamamoto H, Matsubara A, Yasui W and Kikuchi A: Wnt5a signaling is
involved in the aggressiveness of prostate cancer and expression of
metalloproteinase. Oncogene. 29:2036–2046. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Uhm JE, Park YH, Yi SY, et al: Treatment
outcomes and clinicopathologic characteristics of triple-negative
breast cancer patients who received platinum-containing
chemotherapy. Int J Cancer. 124:1457–1462. 2009. View Article : Google Scholar : PubMed/NCBI
|
